Improvements in life expectancy and quality-adjusted life years as a result of chimeric antigen receptor T-cell therapy is dependent upon immediate access to treatment. READ MORE
Improvements in life expectancy and quality-adjusted life years as a result of chimeric antigen receptor T-cell therapy is dependent upon immediate access to treatment.
A JAMA Oncology research letter sheds light on the average additional costs associated with CAR-T therapy, which can be from $30,000 to $36,000 per patient.
Medicare will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000.
Younger patients who received certain chemotherapies for solid tumors or leukemia may not have T-cells capable of becoming effective CAR T-cells.
Authors review the foundational research in CAR-T therapy, including pricing estimates, in order to determine how best to integrate this new branch of immuno-oncology into clinical pathways for patients with B-cell malignancies.
Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?
Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.
What is the average cost per patient for additional therapy or adverse events after CAR-T therapy administration?
A recent study found that patients with non-Hodgkin lymphoma who received CAR-T therapy benefited, with an overall response rate of what percentage after a median of 15.4 months?
A recent study sought to determine the factors associated with durable remission after a complete response to CD19-targeting chimeric antigen receptor T-cell therapy in adult patients with B-cell acute lymphoblastic leukemia.
Real-World Study Determines Effectiveness of Targeted Therapy for Relapsed, Refractory B-Cell Malignancy
A recent study demonstrated the real-world effectiveness and tolerability of a targeted agent for the treatment of relapsed or refractory mantle cell lymphoma.
A recent study found that a biosimilar provides improved outcomes without increased risk of toxicity for patients with DLBCL and treatment-induced neutropenia.